The Dutch infrastructure for cancer-specific ATMP Research (DARE-NL) is a unique partnership between all academic developers of Advanced Therapy Medicinal Products (ATMPs) in the Netherlands. ATMPs are the next revolution in medicine promising a leap in survival, quality of life and cure for cancer patients. Although many novel ATMPs are under development in academic centers, the steps toward market approval and clinical application are complex and do not fit the traditional frameworks. The overarching goal of DARE-NL is to accelerate clinical testing of novel ATMPs for cancer patients to ensure timely and sustainable access to potentially curative treatment options for cancer patients. To reach this goal, DARE-NL was funded by the Dutch Cancer Society (KWF) to establish a national infrastructure and connect all relevant stakeholders (e.g. scientists, clinicians, pharmacists, regulatory agencies, patient advocates) in the ATMP development cycle. Specifically, DARE-NL centralizes knowledge, harmonizes protocols, develops raw materials, biologics, assays and technologies, and facilitates implementation and patient outreach by:
Connecting
- translational ATMP expertise in academic centers in the Netherlands
- with policymakers and regulatory scientists in the Netherlands and the EU through centralized dialogues
- with existing (inter)national ATMP oncology structures
Harmonizing
- and exchanging procedures, QC protocols and processes
- by mapping the need for translation of next-generation technologies in ATMP production
Facilitating
- establishing academic manufacturing of key good manufacturing practice (GMP) ingredients
- establishing an ATMP education program
- establishing a sustainable knowledge exchange platform
Collaborating Organizations
